Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anastrozole
Drug ID BADD_D00142
Description Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer.[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne.[A186865] Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995.[L8863]
Indications and Usage Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women.[L8863] It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].[L8866,L8863]
Marketing Status approved; investigational
ATC Code L02BG03
DrugBank ID DB01217
KEGG ID D00960
MeSH ID D000077384
PubChem ID 2187
NDC Product Code 38779-2555; 58623-0041; 73377-120; 65841-743; 70518-2420; 0310-0201; 51927-4435; 68071-1543; 68071-2791; 46014-1009; 69988-0013; 71052-248; 63187-080; 63629-5269; 70518-2484; 59651-236; 63850-0010; 71335-1879; 0904-6195; 46014-1160; 61200-104; 68554-0026; 16571-421; 0093-7536; 51991-620; 68382-209; 63850-6527; 50090-2453; 50090-5812; 68001-155; 65072-0702; 65129-1119; 16729-035; 42291-016; 50268-075; 60687-112; 68071-5203; 62991-3176; 43063-383; 62559-670; 72789-008; 55111-814; 62135-490; 72189-415; 53104-7627; 65096-0117; 42291-085; 76420-004; 51552-1568; 60440-2921; 62157-077; 62756-428; 82393-201
Synonyms Anastrozole | 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) | Anastrazole | Arimidex | ICI D1033 | ZD-1033 | ZD 1033 | Zeneca ZD 1033 | ZD1033
Chemical Information
Molecular Formula C17H19N5
CAS Registry Number 120511-73-1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal rigidity07.01.05.011--Not Available
Abnormal dreams19.02.03.001; Available
Acne23.02.01.0010.000238%Not Available
Acute febrile neutrophilic dermatosis01.02.01.006; Available
Acute hepatic failure09.01.03.0010.000556%Not Available
Acute myeloid leukaemia16.01.05.001; Available
Acute promyelocytic leukaemia16.01.05.003; Available
Affective disorder19.04.04.0010.000159%Not Available
Ageusia17.02.07.001; Available
Alanine aminotransferase increased13.03.04.005--
Amblyopia06.02.01.0010.000318%Not Available
Anaphylactic reaction24.06.03.006;
Anaphylactic shock24.06.02.004; Available
Anaphylactoid reaction24.06.03.007; Available
Anger19.04.02.0010.000238%Not Available
Angina pectoris02.02.02.002;
Angioedema22.04.02.008;; Available
Arthropathy15.01.01.0030.000985%Not Available
Aspartate aminotransferase increased13.03.04.011--
The 1th Page    1 2 3 4 5    Next   Last    Total 16 Pages
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene